{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T09:47:29Z","timestamp":1743760049415},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,10]]},"DOI":"10.7759\/cureus.64265","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T19:09:53Z","timestamp":1720638593000},"source":"Crossref","is-referenced-by-count":1,"title":["Equine Pergolide Toxicity: A Case Series"],"prefix":"10.7759","author":[{"given":"Natalie E","family":"Ebeling-Koning","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John T","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John  D","family":"DelBianco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan M","family":"Surmaitis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2023.2268981","article-title":"2022 annual report of the National Poison Data System(\u00ae) (NPDS) from America's Poison Centers(\u00ae): 40th annual report","volume":"61","author":"Gummin DD","year":"2023","unstructured":"Gummin DD, Mowry JB, Beuhler MC, et al.. 2022 annual report of the National Poison Data System(\u00ae) (NPDS) from America's Poison Centers(\u00ae): 40th annual report. Clin Toxicol (Phila). 2023, 61:717-939. 10.1080\/15563650.2023.2268981","journal-title":"Clin Toxicol (Phila)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.133165","article-title":"Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-hydroxytryptamine2B and 5-hydroxytryptamine2A receptors","volume":"324","author":"G\u00f6rnemann T","year":"2008","unstructured":"G\u00f6rnemann T, H\u00fcbner H, Gmeiner P, Horowski R, Latt\u00e9 KP, Flieger M, Pertz HH. Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-hydroxytryptamine2B and 5-hydroxytryptamine2A receptors. J Pharmacol Exp Ther. 2008, 324:1136-45. 10.1124\/jpet.107.133165","journal-title":"J Pharmacol Exp Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/vetsci9100556","article-title":"Pituitary pars intermedia dysfunction (PPID) in horses","volume":"9","author":"Kirkwood NC","year":"2022","unstructured":"Kirkwood NC, Hughes KJ, Stewart AJ. Pituitary pars intermedia dysfunction (PPID) in horses. Vet Sci. 2022, 9:10.3390\/vetsci9100556","journal-title":"Vet Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.64.12.1721","article-title":"Heart valve regurgitation, pergolide use, and Parkinson disease: an observational study and meta-analysis","volume":"64","author":"Corvol JC","year":"2007","unstructured":"Corvol JC, Anzouan-Kacou JB, Fauveau E, et al.. Heart valve regurgitation, pergolide use, and Parkinson disease: an observational study and meta-analysis. Arch Neurol. 2007, 64:1721-6. 10.1001\/archneur.64.12.1721","journal-title":"Arch Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade R","year":"2007","unstructured":"Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007, 356:29-38. 10.1056\/NEJMoa062222","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini R","year":"2007","unstructured":"Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007, 356:39-46. 10.1056\/NEJMoa054830","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/0192623310378027","article-title":"Drug-induced valvulopathy: an update","volume":"38","author":"Elangbam CS","year":"2010","unstructured":"Elangbam CS. Drug-induced valvulopathy: an update. Toxicol Pathol. 2010, 38:837-48. 10.1177\/0192623310378027","journal-title":"Toxicol Pathol"},{"key":"ref8","article-title":"How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009","volume":"8","author":"Lexchin J","year":"2014","unstructured":"Lexchin J. How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009. Open Med. 2014, 8:14-19.","journal-title":"Open Med"},{"key":"ref9","unstructured":"Economic impact study of the Unites States horse industry. (2017). Accessed. June 4, 2024: https:\/\/horsecouncil.org\/resources\/2017-economic-impact-study-facts\/."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/VMRR.S74191","article-title":"Equine pituitary pars intermedia dysfunction: current perspectives on diagnosis and management","volume":"6","author":"Spelta CW","year":"2015","unstructured":"Spelta CW. Equine pituitary pars intermedia dysfunction: current perspectives on diagnosis and management. Vet Med (Auckl). 2015, 6:293-300. 10.2147\/VMRR.S74191","journal-title":"Vet Med (Auckl)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a review","volume":"323","author":"Armstrong MJ","year":"2020","unstructured":"Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020, 323:548-60. 10.1001\/jama.2019.22360","journal-title":"JAMA"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.12.026","article-title":"The management of restless legs syndrome: an updated algorithm","volume":"96","author":"Silber MH","year":"2021","unstructured":"Silber MH, Buchfuhrer MJ, Earley CJ, Koo BB, Manconi M, Winkelman JW. The management of restless legs syndrome: an updated algorithm. Mayo Clin Proc. 2021, 96:1921-37. 10.1016\/j.mayocp.2020.12.026","journal-title":"Mayo Clin Proc"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.57.10.1461","article-title":"Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease","volume":"57","author":"Kujawa K","year":"2000","unstructured":"Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch Neurol. 2000, 57:1461-3. 10.1001\/archneur.57.10.1461","journal-title":"Arch Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2165\/11318330-000000000-00000","article-title":"Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease","volume":"27","author":"Wood LD","year":"2010","unstructured":"Wood LD. Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease. Drugs Aging. 2010, 27:295-310. 10.2165\/11318330-000000000-00000","journal-title":"Drugs Aging"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15506","article-title":"Ropinirole-associated orthostatic hypotension as cause of a prescribing cascade in an elderly man","volume":"13","author":"Becerra AF","year":"2021","unstructured":"Becerra AF, Boch M, Al-Mezrakchi YA. Ropinirole-associated orthostatic hypotension as cause of a prescribing cascade in an elderly man. Cureus. 2021, 13:10.7759\/cureus.15506","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-017-0615-7","article-title":"Pramipexole overdose associated with visual hallucinations, agitation and myoclonus","volume":"13","author":"Cardon-Dunbar A","year":"2017","unstructured":"Cardon-Dunbar A, Robertson T, Roberts MS, Isbister GK. Pramipexole overdose associated with visual hallucinations, agitation and myoclonus. J Med Toxicol. 2017, 13:343-6. 10.1007\/s13181-017-0615-7","journal-title":"J Med Toxicol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-018-4937-3","article-title":"Prevalence of nausea and vomiting in adults using ropinirole: a systematic review and meta-analysis","volume":"63","author":"Kurin M","year":"2018","unstructured":"Kurin M, Bielefeldt K, Levinthal DJ. Prevalence of nausea and vomiting in adults using ropinirole: a systematic review and meta-analysis. Dig Dis Sci. 2018, 63:687-93. 10.1007\/s10620-018-4937-3","journal-title":"Dig Dis Sci"},{"key":"ref18","article-title":"Poisoning or overdose-related hypotension","author":"Smollin C","year":"2024","unstructured":"Smollin C. Poisoning or overdose-related hypotension. Current Medical Diagnosis & Treatment 2024. Papadakis MA, McPhee SJ, Rabow MW, McQuaid KR, Gandhi M (ed): McGraw-Hill Education, 2024."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199039030-00009","article-title":"Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease","volume":"39","author":"Langtry HD","year":"1990","unstructured":"Langtry HD, Clissold SP. Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease. Drugs. 1990, 39:491-506. 10.2165\/00003495-199039030-00009","journal-title":"Drugs"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/00019052-200312001-00003","article-title":"The pharmacokinetics of pergolide in Parkinson's disease","volume":"16","author":"Blin O","year":"2003","unstructured":"Blin O. The pharmacokinetics of pergolide in Parkinson's disease. Curr Opin Neurol. 2003, 16:9-12. 10.1097\/00019052-200312001-00003","journal-title":"Curr Opin Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/254442-equine-pergolide-toxicity-a-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T19:09:58Z","timestamp":1720638598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/254442-equine-pergolide-toxicity-a-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.64265","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,10]]}}}